Initiation of Antiresorptive Drug Treatment during Endocrine Therapy for Breast Cancer—A Retrospective Cohort Study of 161,492 Patients in Germany

SIMPLE SUMMARY: Endocrine therapy (ET), which significantly reduces breast cancer (BC) recurrence and mortality rates, is the primary systemic therapy for hormone receptor positive BC. However, in addition to frequently reported TAM- and AI-related side effects, such as hot flashes, arthralgias, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gremke, Niklas, Griewing, Sebastian, Kadys, Arturas, Kostev, Karel, Wagner, Uwe, Kalder, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047063/
https://www.ncbi.nlm.nih.gov/pubmed/36980733
http://dx.doi.org/10.3390/cancers15061847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047063/
https://www.ncbi.nlm.nih.gov/pubmed/36980733
http://dx.doi.org/10.3390/cancers15061847

Ejemplares similares